Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective raised by Wedbush from $48.00 to $50.00 in a research note released on Tuesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

A number of other equities analysts also recently commented on KNSA. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $52.33.

Kiniksa Pharmaceuticals International Trading Down 6.1%

Kiniksa Pharmaceuticals International stock opened at $38.60 on Tuesday. The firm has a market cap of $2.93 billion, a P/E ratio of 85.78 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 1-year low of $18.12 and a 1-year high of $44.42. The firm has a 50-day moving average of $41.33 and a 200-day moving average of $36.58.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. The firm’s revenue for the quarter was up 61.2% on a year-over-year basis. Research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barry D. Quart sold 20,129 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at approximately $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 510,689 shares of company stock worth $20,009,290. 53.48% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KNSA. Savant Capital LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $398,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $1,648,000. Asset Management One Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 624.2% in the 2nd quarter. Asset Management One Co. Ltd. now owns 13,470 shares of the company’s stock worth $373,000 after purchasing an additional 11,610 shares in the last quarter. Franklin Resources Inc. grew its position in Kiniksa Pharmaceuticals International by 62.2% during the 2nd quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock valued at $3,004,000 after purchasing an additional 41,632 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $20,349,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.